Wire · operational-macro
FDA Broadens Anktiva Indication to Cover Both CIS and Papillary-Only BCG-Unresponsive NMIBC
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 15 October 2026 · Fusion42 review
The FDA has expanded the indication for Anktiva (nogapendekin alfa inbakicept-pmln) in combination with BCG to include patients with BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC) with papillary-only tumors, in addition to those with carcinoma in situ (CIS). This marks the first approved therapy for BCG-unresponsive NMIBC with papillary-only tumors.
This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it between 14 Oct 2026 and 15 Oct 2026.
◆ ◆ The Wire takeaway
You can now target a broader bladder cancer patient group with Anktiva after FDA expanded its use to papillary-only tumors. This opens a new market for therapies aimed at BCG-unresponsive NMIBC patients who previously had fewer options.
◆ Coverage
3 sources · first reported 14 Oct 2026 · latest 15 Oct 2026
◆ Related on Wire
◆ Topics